Gilgamesh Pharmaceuticals vs Alphabet Inc.
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage psychedelic pharma developing novel psilocybin-derived bretisilocin in Phase 2 for depression; first YC-backed psychedelics company competing with COMPASS Pathways.
About
Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing novel psychedelic-derived compounds for treatment-resistant depression, anxiety, and stress-related psychiatric disorders — pursuing a drug discovery approach that modifies psychedelic molecular structures to optimize therapeutic effects (efficacy, duration) while retaining or modifying the subjective psychedelic experience. Founded by Jonathan Sporn MD, Dalibor Sames PhD, Andrew Kruegel PhD, Jeff Witkin PhD, and Mike Cunningham PhD, Gilgamesh was the first Y Combinator-backed company in the psychedelic therapeutics space.\n\nGilgamesh's lead compound bretisilocin (GM-2505) is a novel psilocybin-derived molecule in Phase 2 clinical trials for major depressive disorder, positioned as a potential best-in-class psychedelic compound with optimized pharmacokinetics. The company's scientific founders from Columbia University brought expertise in psychedelic pharmacology and medicinal chemistry that enables rational drug design rather than simply repurposing existing natural psychedelics like psilocybin. The differentiated compound IP strategy creates defensible pharmaceutical assets rather than relying on natural compound exclusivity.\n\nIn 2025, Gilgamesh competes in the psychedelic medicine market with COMPASS Pathways (psilocybin for treatment-resistant depression, furthest along in clinical trials), Usona Institute (psilocybin non-profit research), MindMed (LSD and MDMA derivatives), and Lykos Therapeutics (MDMA-assisted therapy) for psychedelic-derived psychiatric treatment development. The FDA declined to approve MDMA-assisted therapy in 2024 (Lykos), creating caution around psychedelic clinical timelines, while COMPASS continues Phase 3 trials for psilocybin. Gilgamesh's novel compound approach (not psilocybin itself) provides a distinct regulatory and IP path. The 2025 strategy focuses on Phase 2 data readouts for bretisilocin, building clinical evidence for the compound's differentiated profile, and advancing toward a Phase 3 pivotal trial design.
Mountain View AI and digital advertising conglomerate (NASDAQ: GOOGL) $350B FY2024 revenue (+15%); Google Search 90%+ share, Google Cloud $43.2B (+30%), Gemini AI, DOJ monopoly ruling 2024.
About
Alphabet Inc. is a Mountain View, California-based technology conglomerate — publicly traded on the NASDAQ (NASDAQ: GOOGL, GOOG) as an S&P 500 Information Technology component — operating as the holding company for Google (Search, YouTube, Google Ads, Gmail, Google Cloud, Android, Chrome, Maps, Play Store, Workspace), and Other Bets (Waymo autonomous vehicles, DeepMind AI research, Verily life sciences, Wing drone delivery, Google Fiber) through approximately 183,000 full-time employees. In fiscal year 2024, Alphabet reported revenues of $350 billion (+15% year-over-year), with Google Services (Search, YouTube, Google Play, subscriptions) generating $307 billion, Google Cloud generating $43.2 billion (+30%), and Other Bets $2.0 billion, while generating $100 billion in net income — reflecting Alphabet's position as one of the highest-profit companies in history, funded by Google Search's advertising monopoly (processing 8.5+ billion searches daily, commanding 90%+ global search market share). CEO Sundar Pichai has prioritized Alphabet's AI-first transformation: the 2024 launch of Gemini Ultra 1.0, Gemini 1.5 Pro (1 million token context window — largest at launch), and Gemini 2.0 Flash positioned Google as a competitive AI frontier model lab alongside OpenAI, following the ChatGPT disruption that temporarily threatened Google's search advertising dominance in 2023. Google Cloud's Vertex AI platform (enterprise AI model deployment with Gemini, Llama, and third-party models) and Google Distributed Cloud (air-gapped government cloud) compete directly with Microsoft Azure AI and AWS SageMaker for enterprise AI workload contracts. Waymo's commercial robotaxi operations in San Francisco, Phoenix, and Los Angeles (Waymo One — fully driverless rides, generating revenue and operational data) represent Alphabet's highest-upside long-duration investment.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.